This brings the total capital raised to nearly USD 10m
AgilVax is a New Mexico biopharmaceutical company that discovers and develops targeted antibody-based products to treat multiple types of cancer.
The company has three development programmes; an antibody-drug conjugate targeting xCT, an unmodified monoclonal antibody targeting xCT, and AX09, a VLP-based xCT vaccine.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886